drugset / Trial / NCT01675297

Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis

NCT01675297

Phase 4 Completed 1053 enrolled Hanlim Pharm. Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and the safety of Risedronate, cholecalciferol combination tablet in patients with Osteoporosis.

Timeline

Start
2011-07-04
Primary completion
2013-12
Completion
2014-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified
Comparator Risedronate Small molecule 35 mg

Indications